VRDN-006 — Full data
2026
Viridian anticipates sharing development plans for VRDN-006 in 2026.Source filing
VRDN biotech catalysts & pipeline
VIRIDIAN THERAPEUTICS INC · Data as of 2026-10-25
Upcoming catalysts
VRDN-008 — Initial data
2H 2026
Data remains on track for 2H 2026.Source filing
anti-thyroid-stimulating hormone receptor antibody — IND submission
Q4 2026
Viridian plans to submit an Investigational New Drug (IND) application in Q4 2026.Source filing
anti-TSHR candidate — IND submission
Q4 2026
We anticipate submitting an IND for this program in the fourth quarter of 2026.Source filing
TSHR antibody — IND submission
Q4 2026
Viridian plans to submit an Investigational New Drug (IND) application in Q4 2026 and expects to develop this program in TED and Graves' disease.Source filing
elegrobart — NDA/BLA submission
Q1 2027
Viridian is on track to submit a Biologics License Application (BLA) to the FDA for elegrobart in Q1 2027.Source filing